|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **All episodes**n=117 | **Recurrent AP**n=58 | **First-time AP**n=59 | **P** |
| **Moderate-severe AP, n (%)** | 15 (12.8%) | 7 (12.1%) | 8 (13.6%) | 0.81 |
|  |  |  |  |  |
| **Demographics** |  |  |  |  |
|  **-males, n (%)** | 56 (47.9%)  | 22 (37.9%) | 34 (57.6%) | **0.03** |
|  **-age, years** | 13.2 (7.0-15.9) | 14.4 (11.9-16.2) | 11.3 (5.9-15.4) | **<0.01** |
|  **-weight percentile for age & sex** | 63 (32-79) | 71 (54-79) | 54 (17-74) | **0.03** |
|  |  |  |  |  |
|  |  |  |  |  |
| **Admission laboratory results** |  |  |  |  |
| **CBC** |  |  |  |  |
|  **-hemoglobin, g/dL** | 13.1 (1.7) | 13.3 (1.8) | 12.9 (1.7) | 0.24 |
|  **-hematocrit, %** | 38.7 (4.8) | 39.1 (4.7) | 38.4 (5.0) | 0.42 |
|  **-WBC, 109/L** | 12.2 (9.2-15.4) | 12.6 (10.1-15.5) | 11.4 (8.1-15.0) | 0.18 |
|  **-platelet, 109/L** | 306 (263-367) | 302 (264-319) | 324 (265-399) | 0.15 |
|  |  |  |  |  |
| **Biochemistry** |  |  |  |  |
|  **-glucose, mg/dL** | 101 (90-122) | 96 (88-122) | 105 (95-122) | 0.09 |
|  **-sodium, mmol/L** | 138 (136-141) | 139 (137-141) | 138 (136-140) | 0.13 |
|  **-calcium, mg/dL** | 9.3 (0.5) | 9.4 (0.6) | 9.3 (0.5) | 0.31 |
|  **-chloride, mmol/L** | 104 (3.3) | 104.9 (2.3) | 102.6 (3.7) | **<0.01** |
|  **-creatinine, mg/dL** | 0.7 (0.6-0.8) | 0.7 (0.6-0.9) | 0.7 (0.6-0.8) | 0.19 |
|  **-BUN, mg/dL** | 11 (9-13) | 11.0 (10.0-14.0) | 11.0 (9.0-13.0) | 0.45 |
|  **-albumin, g/L** | 43.0 (4.4) | 43.4 (3.7) | 42.5 (4.9) | 0.33 |
|  **-ALT, U/L** | 15 (11-23) | 14 (12-19) | 18 (11-40) | **0.02** |
|  **-gGT, U/L** | 11 (8-27) | 11 (9-24) | 13 (8-50) | **0.02** |
|  **-total cholesterol, mg/dL**  | 140 (125-167) | 134 (123-148) | 143 (129-170) | 0.07 |
|  **-triglycerides, mg/dL** | 76 (54-115) | 75 (57-99) | 81 (53-122) | 0.24 |
|  **-amylase, U/L** | 485 (201-1054) | 491 (263-1080) | 485 (150-918) | 0.26 |
|  **-lipase, U/L** | 743 (265-1360) | 840 (488-1992) | 485 (191-1129) | **0.02** |
|  |  |  |  |  |
| **Pancreatic imaging (n=90), n (%)** |  | n=37 | n=53 |  |
|  **-non-specific inflammation\*** | 57 (63.3%) | 27 (73.0%) | 30 (56.6%) | 0.11 |
|  **-peripancreatic fluid collection** | 14 (15.6%) | 7 (18.9%) | 7 (13.2%) | 0.46 |
|  **-pancreatic necrosis** | 2 (2.2%) | 0 | 2 (3.8%) | 0.51 |
|  **-cholelithiasis** | 9 (10.0%) | 2 (5.4%) | 7 (13.2%) | 0.30 |
|  **-normal imaging** | 27 (30.0%) | 10 (27.0%) | 23 (43.4%) | 0.11 |
|  |  |  |  |  |
| **Clinical course** |  |  |  |  |
| **symptoms duration****prior to admission, days** | 1 (1-3) | 1 (1-2) | 2 (1-5) | **<0.01** |
| **Treatment, n (%)** |  |  |  |  |
|  **-NGT feeding** | 22 (18.8%) | 10 (17.2%) | 12 (20.3%) | 0.67 |
|  **-TPN** | 14 (12.0%) | 6 (10.3%) | 8 (13.6%) | 0.59 |
|  **-Antibiotics** | 24 (20.5%) | 5 (8.6%) | 19 (32.2%) | **<0.01** |
| **Interventions, n (%)** |  |  |  |  |
|  **-all** | 14 (12.0%) | 11 (19.0%) | 3 (5.1%) | **0.02** |
|  **-ERCP** | 4 (3.4%) | 4 (6.9%) | 0 | 0.06 |
|  **-ERCP + stenting** | 7 (6.0%) | 6 (10.3%) | 1 (1.7%) | 0.06 |
|  **-CT guided collection drainage** | 1 (0.9%) | 1 (1.7%) | 0 | 0.50 |
|  **-endoscopic cyst drainage** | 1 (0.9%) | 0 | 1 (1.7%) | 1.0 |
|  **-surgery** | 1 (0.9%) | 0 | 1 (1.7%) | 1.0 |
|  |  |  |  |  |
| **Analgesics, maximal class (n=86), n (%)** |  | n=45 | n=41 | 0.06 |
|  **-non-opioids** | 64 (74.4%) | 28 (62.2%) | 36 (87.8%) | **<0.01** |
|  **-mild opioids** | 7 (8.1%) | 6 (13.3%) | 1 (2.4%) | 0.11 |
|  **-strong opioids** | 13 (15.1%) | 9 (20.0%) | 4 (9.8%) | 0.13 |
|  **-any opioids** | 20 (23.2%) | 15 (33.3%) | 5 (12.2%) | **0.02** |
|  **-no analgesics** | 2 (2.3%) | 2 (4.4%) | 0 | 0.50 |
|  |  |  |  |  |
| **Hospitalization duration, days** | 5.0 (4-8) | 5 (4-9) | 6 (4-8) | 0.30 |
|  |  |  |  |  |
| **Presumed diagnosis, n (%)** |  |  |  | **<0.01** |
|  **-anatomic anomaly** | 19 (16.2%) | 16 (27.6%) | 3 (5.1%) | **<0.01** |
|  **-medication associated** | 14 (12.0%) | 2 (3.4%) | 12 (20.3%) | **<0.01** |
|  **-cholelithiasis** | 9 (7.7%) | 3 (5.2%) | 6 (10.2%) | 0.49 |
|  **-post-ERCP** | 4 (3.4%) | 3 (5.2%) | 1 (1.7%) | 0.36 |
|  **-trauma** | 3 (2.6%) | 0 | 3 (5.1%) | 0.24 |
|  **-idiopathic** | 68 (58.1%) | 34 (58.6%) | 34 (57.6%) | 0.91 |

**Supplementary Table 2. First-time AP episodes compared to AP recurrences- severity, demographics and clinical course.**

Values are presented as number of patients (%), means (standart deviation), median (25-75% interquartile range). Student t-test and Wilcoxon test were used for continuous variables, and categorical variables were compared by the Pearson χ2-test or Fisher Exact test; all tests were done using 2 sided tails with a confidence interval of 95%. AP- acute pancreatitis; WBC- white blood cells; BUN- blood urea nitrogen; ALT- alanine transaminase; gGT- gamma-glutamiltransferase; CRP- C reactive protein; NGT- nasogastric tube; ERCP- endoscopic retrograde cholangio-pancreatography.

\*non-specific inflammation findings- including pancreatic edema, pancreatic enlargement and/or small amount of peri-pancreatic fluid.